FDC Limited's shares saw a notable decline following the announcement of its mixed Q2 results for the financial year 2024-2025 (Q2FY25). While the company reported growth in profits, other performance indicators presented a less optimistic picture. The pharmaceutical company's stock fell nearly 5% on the Bombay Stock Exchange (BSE) despite an uptick in net profit. Investors evaluating FDC's financial health may be rethinking their strategy as they weigh the implications of these results.
FDC shares fall despite PAT growth
On Thursday, FDC shares dropped by 4.8%, reaching an intraday low of ₹522 per share on the BSE. By around 10:27 AM, the stock price had settled at ₹525 per share, marking a 4.34% decrease. In comparison, the BSE Sensex fell 1.15% to 79,453.81. Despite the recent dip, FDC has experienced an overall 52.5% gain over the past year, outperforming the Sensex's rise of 24%. However, for those looking to invest in stocks, this recent decline may signal caution.
Mixed Q2 results impact investor sentiment
FDC's Q2 report, released post-market hours on Wednesday, highlighted mixed performance metrics that likely influenced the recent share movement. The company's consolidated net profit rose by 3% to ₹72 crore compared to ₹70 crore year-on-year (YoY). Revenue for the quarter also climbed, reaching ₹514 crore, an increase of 5.7% from the previous year's figure of ₹486 crore.
However, challenges emerged in other areas. Earnings before interest, tax, depreciation, and amortisation (EBITDA) dropped 7%, down to ₹80 crores from ₹86 crores last year. The EBITDA margin similarly contracted, declining by 220 basis points to 15.5% from 17.7%. This reduction in operating margins might concern those planning to invest in stocks with consistent earnings growth.
Key performance indicators
Below is a summary of FDC's Q2 performance, highlighting the results that have contributed to the mixed investor sentiment:
Investors looking to invest in stocks should consider these indicators to assess the company's profitability and efficiency trends.
FDC's market position and export focus
FDC Limited, headquartered in Mumbai, is a well-established player in India's pharmaceutical sector, known for producing high-quality generics, antibiotics, and nutraceuticals. Founded in 1936, the company has expanded its footprint internationally, with exports spanning over 50 countries across Europe, Africa, Asia, and the Middle East. FDC's ability to serve both domestic and global markets underscores its robust business model. For investors exploring opportunities to invest in stocks within the healthcare and pharmaceutical sectors, FDC's diversified market reach is an attractive attribute.
Stock performance and outlook
The company's market capitalisation stood at ₹8,547.53 crores, with a 52-week high of ₹659 per share and a 52-week low of ₹355.9. This fluctuation presents potential for both gains and losses, depending on market conditions and FDC's future performance. The recent 4.8% drop might offer an entry point for those looking to invest in stocks with growth potential, especially given FDC's 52.5% growth over the past year. However, the decline in EBITDA and operating margins may indicate cost pressures that investors should watch.
For android only